18% Injectable Solution for Cattle
ANTIMICROBIAL DRUG 180 mg of tildipirosin/mL
For subcutaneous injection in beef and non-lactating dairy cattle only.
Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
BRIEF SUMMARY: for full prescribing information use package insert.
INDICATIONS: Zuprevo™ 18% is indicated for
the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni.
WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.
Avoid direct contact with skin and eyes. If accidental eye exposure occurs, rinse eyes with clean water. If accidental skin exposure occurs, wash the skin immediately with soap and water. Tildipirosin may cause sensitization by skin contact.
For technical assistance or to report a suspected adverse reaction, call: 1-800-219-9286.
For customer service or to request a Material Safety Data Sheet (MSDS), call: 1-800-211-3573. For additional Zuprevo 18% information go to
www.zuprevo.com.
For a complete listing of adverse reactions for Zuprevo 18% reported to CVM see:
http://www.fda.gov/AnimalVeterinary/SafetyHealth.
DO NOT USE ZUPREVO 18% IN SWINE. Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.
RESIDUE WARNING: Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.
PRECAUTIONS: The effects of Zuprevo 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond the slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.
• weaning weights • pregnancy percentage from the
previous year • calving percentage • calving interval “The purpose of the production
component is to identify the past production level and then, more importantly, to determine where production loss is occurring,” Bev- ers says. “The resources should be analyzed to determine their perfor- mance and effects on the production and fi nancial situation.” Bevers breaks down these re-
sources into 4 categories: • Natural resources — such
as the pastures, includ- ing the past stocking rate of the ranch, the amount of feed or hay that was fed the past year and the salt and mineral program during the past year. This can help determine if a production loss is occurring due to a mineral defi ciency. • Human resources — if there
are employees, do they understand their role in moving the ranch for- ward towards its goals? Production loss, which infl uences the fi nancial performance, may be occurring due to a lapse of the employees. “It may not be enough to check calving heifers every 2 days,” Bevers says. • Machinery and equipment
Made in Germany
Distributed by: Intervet Inc d/b/a Merck Animal Health, Summit, NJ 07901 Copyright © 2011, Intervet Inc., a subsidary of Merck & Co. All rights reserved.
resources — repairs and mainte- nance are major expenses for many ranches. Assess the condition of the machinery and equipment. Fi- nally, the building and improve- ment resources should be outlined. “The condition of fences can be a major issue,” Bevers says. “Are the current water resources (tanks or windmills) conducive for the full utilization of the pastures?” • Financial situation and per-
US 3448_IV
formance evaluation — again, SPA provides a good fi nancial analy-
S511-25732-2_Zuprevo PI-THIRD
PAGE-2_125X10.indd 1
Size: T - 2.125” x 10” Updated 2-11-13
2/11/13 3:42 PM 66 The Cattleman March 2013
thecattlemanmagazine.com
sis of the p er f o r- mance of the cow- calf opera- tion. “Mini- mal items to include here are net income from operations, net income per breeding female, the total expenses of the operation and total cost per breeding female,” Bevers says.
The rate of return
on the operations assets and a breakdown of the expenses should also be examined. Know the largest expenses of the operation. “Once the largest expenses are identifi ed, the manager should ask if they can be explained, then determine whether these expenses are manageable in the short term or the long term,” Bevers says. For example, compare high feed
costs versus high depreciation costs. Short-term high feed costs can be at- tributed to drought or other weather situations. High depreciation costs can be explained, but can’t nec- essarily be alleviated in the short term. A detailed fi rst section of the
ranch plan leads to the second sec- tion, which again details where the ranch is expected to be at the end of next year. “The second section is relatively easy to complete if every- one agrees on the overall goals of the operation,” Bevers says. “A path should be set by everyone involved
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126